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Introduction
Erythropoiesis is the process of producing and replenishing the number of circulating red blood cells (RBCs). There are two unique waves of erythropoiesis: the primitive wave and the definitive wave. Erythropoiesis is tightly controlled and regulated by a balance of cell proliferation, differentiation, and survival 1, 2 . The overproduction of RBCs or lack of RBCs can cause human disease. Diamond-Blackfan anemia and sickle cell anemia are two examples of rare congenital anomalies that arise from defects in the production of RBCs 3 , and polycythemia occurs as a consequence of too many RBCs [4] [5] [6] . Genetic disorders of RBCs have revealed critical mediators of erythropoiesis [7] [8] [9] [10] [11] , many of which include transcription factors. For example, Diamond-Blackfan anemia can result from mutations in the transcription factor GATA1 [12] [13] [14] . GATA1 is the founding member of the GATA family of zinc finger transcription factors 15 and interacts with a multitude of other proteins such as Friend of GATA (FOG), EKLF, SP1, p300 and PU.1 to promote erythropoiesis 16 .
Cholesterol is one known regulator of RBC function as it maintains the structure and integrity of the RBC membrane and aids in the protection against oxidative stress [17] [18] [19] [20] [21] [22] . But both in vitro and in vivo studies have raised the possibility that cholesterol biosynthesis regulates the differentiation of RBCs 23, 24 . Knockdown of OSC/LSS, which catalyzes the cyclization of monoepoxysqualene to lanosterol, decreased the self-renewing capacity of K562 cells in vitro and results in increased cell death of progenitor like cells. Follow up in vivo assays have reinforced this premise as reduced cholesterol synthesis was associated with deficits in terminal RBC development 24 . These data provide strong evidence that cholesterol's function in RBCs is not restricted to membrane fluidity.
The cholesterol synthesis pathway (CSP) begins with synthesis of HMG-CoA from aceto-acetyl-CoA, which then undergoes several transformations to produce farnesyl pyrophosphate (FPP). FPP represents a branch point in the pathway, ultimately resulting in the production of cholesterol or isoprenoids [25] [26] [27] . Both classes of lipids have diverse functions spanning membrane fluidity, protein prenylation, and precursors to various different types of molecules including vitamin D3. Cholesterol homeostasis has been previously linked to hematopoietic stem cell (HSC) differentiation 28, 29 and we confirmed that cholesterol synthesis is essential for RBC development 24 . The function of isoprenoids is less clear because isoprenoids give rise to diverse molecules which themselves are critical for cell differentiation [30] [31] [32] [33] .
Here we show that the products of the CSP are essential for RBC development. We show that defects in cholesterol and/or isoprenoids results in deficient numbers of RBCs, but that each lipid regulates RBC number by unique mechanisms. We show that inhibition of isoprenoid synthesis disrupts the number of Gata1 positive cells produced, but the inhibition of cholesterol has no effect on gata1 expression or the number of Gata1 positive cells. Thus, we demonstrate an essential function for the CSP during RBC specification and primitive erythropoiesis.
Methods

Zebrafish Care
For all experiments, embryos were obtained by crossing AB wildtype, Tupfel Long Fin wildtype, or hmgcs1 Vu57 34 . All embryos were maintained in embryo medium at 28 • C and all experiments were performed according to protocol 811689-5 approved by The University of Texas El Paso Institutional Animal Care and Use Committee (IACUC). Genotyping was performed as previously described 35 .
Drug treatments and morpholino injection
Atorvastatin (Sigma, pharmaceutical grade, St. Louis MO), lonafarnib (Sigma, St. Louis MO), and Ro 48 8071 (Santa Cruz Biotechnology, Santa Cruz, CA) were each dissolved in 100% dimethyl sulfoxide (DMSO). Treatment was initiated at the sphere developmental stage (approximately 4-5hpf) and fresh drug was added every 18-24 hours until the harvest time points indicated in the figure legends. Drug concentrations were determined using a gradient of each drug ( Supplementary Figure 1 ) and the concentration selected was based upon working conditions from previous literature. We selected a maximum tolerated sub-lethal dose producing a consistent phenotype according to a Fisher's exact T-test as previously described in Quintana et. al. 2017 35 . Drugs were diluted in embryo medium to make working solutions at the following concentrations: 2.0 uM atorvastatin [34] [35] [36] , 8 uM lonafarnib 34, 37 , and 1.5uM Ro 48 8071. Final concentration of DMSO was less than 0.01 % in all samples and vehicle control treatment. Ro 48 8071 specificity for oxido-squalene synthesis has been previously described 24, 24, 38, 39 . The specificity of lonafarnib has been previously described as a farnyesl protein transferase inhibitor 40 .
For morpholino injections, antisense hmgcs1 morpholinos (AATCATATAACGGTGTTGGTTCGTG) were injected (0.025mM) at the single cell stage and fixed at the indicated time points within the figure legend. For all treatment groups (drug treatment and morpholino) statistical significance was obtained using a Fisher's Exact Test. 
Hemoglobin quantification
For hemoglobin quantification, larvae (numbers indicated in each figure graph) were homogenized with a pestle in purified water at 4 days post fertilization (dpf). Hemoglobin was measured with the Hemoglobin Assay Kit (Sigma-Aldrich, St. Louis, MO) according to manufacturer's protocol. For analysis of the Vu57 allele, larvae were separated via distinct phenotypic hallmarks described previously 34, 35 . The control contained both homozygous wildtype and heterozygous individuals harboring the Vu57 allele. Experiments were performed in a minimum of biological duplicate. For drug treatment assays, wildtype embryos were treated as described above before assaying for hemoglobin concentration. Statistical significance was determined using a T-test.
Whole Mount In Situ Hybridization (WMISH) and Quantitative Real Time PCR (QPCR)
Whole mount in situ hybridization was performed as described by Thisse and Thisse 42 
Confocal Imaging
Embryos were fixed at the given time point and then mounted in 0.6% low melt agar in a glass bottom dish (Fisher, MA). Imaging was performed on a Zeiss LSM 700 at 20X magnification.
Images were restricted to the caudal hematopoietic tissue. For each fish, a minimum of 12-20 zstacks were collected. Statistical significance was obtained using a T-test.
Data Sharing
For access to datasets and protocols please contact corresponding author by email.
Results
Mutations in hmgcs1 disrupt RBC development
Based upon previous data 24 , we sought to determine the number of mature RBCs in a zebrafish harboring mutations in the hmgcs1 gene (Vu57). The Vu57 allele introduces a single missense mutation (H189Q) in the hmgcs1 gene, which encodes the first enzyme in the CSP.
The VU57 allele abrogates cholesterol synthesis causing a multiple congenital anomaly syndrome characterized by defects in myelination, myelin gene expression, cardiac edema, pigment defects and craniofacial abnormalities 34, 35 . We first detected the number of We next quantified the decrease in circulating RBCs in homozygous mutants and their siblings. We performed a quantitative measure of total hemoglobin content using a colorimetric assay in which endogenous hemoglobin can be measured quantitatively at a wavelength of 400nm 44 . In order to measure the levels of hemoglobin in siblings and Vu57 carriers, homozygous Vu57 larval were separated according phenotype at 3 dpf 34 and the total hemoglobin content of homozygous carriers was compared to the hemoglobin content of wildtype and heterozygous siblings at 96 hpf. Phenotypic hallmarks of the Vu57 allele include craniofacial abnormalities and cardiac edema 34 . As shown in Figure 1C , the total hemoglobin content in homozygous carriers of the Vu57 allele was decreased by approximately 20% (p<0.05). Taken together these data suggest that mutations in hmgcs1 disrupt RBC development.
Mutation of hmgcs1 disrupts the expression of markers associated with RBC differentiation.
One possible explanation for the loss of total hemoglobin content observed in larvae carrying the Vu57 allele could stem from an inability to produce globin mRNA. To determine whether mutations in hmgcs1 interfere with globin expression, we performed whole mount in situ hybridization (ISH) at 26 hpf with an anti-hbbe1.1 riboprobe. hbbe1.1 was expressed in the caudal intermediate cell mass (ICM) of wildtype siblings and the onset of circulation was readily apparent as hbbe1.1 mRNA was detected over the yolk sac ( Figure 2A ). hbbe1.1 expression was up-regulated in Vu57 embryos with expression that localized throughout the entire ICM and was not restricted to the most caudal region ( Figure 2B arrowhead) . In addition, hbbe1.1 expression over the yolk sac was increased relative to wildtype siblings at 26 hpf ( Figure 2A&B ).
We next measured the expression of alas2, which encodes the first enzyme in heme biosynthesis 45 . Wildtype siblings expressed appropriate alas2 expression in the caudal ICM at 26 hpf ( Figure 2C ), but the level of alas2 in embryos with the Vu57 allele was spatially disrupted spanning the entire ICM ( Figure 2D arrowhead) and increased relative to wildtype siblings.
These data are consistent with the level and spatial expression of hbbe1.1, as alas2 is known to modulate the levels of globin 46 . Taken together, these data demonstrate that mutant embryos maintain the expression of globin and some of the enzymes necessary for heme synthesis.
gata1a expression is decreased in hmgcs1 mutant embryos.
Given the abnormal expression of globin (hbbe1.1), we hypothesized that the mutation of hmgcs1 disrupts the expression of GATA1, a known regulator of globin expression. We measured the expression of gata1a, the zebrafish ortholog of GATA1 using ISH and quantitative PCR (QPCR) at 18 somites and 26 hpf in mutants and their wildtype siblings. At 18 somites, wildtype siblings expressed gata1a in the caudal ICM ( Figure 3A, dorsal view) , but the Vu57 allele resulted in decreased gata1a expression ( Figure 3A-B arrowheads) . This decrease in gata1a persisted through the onset of circulation, as we observed reduced gata1a expression at 26hpf ( Figure 3C -D, arrowhead). We next quantified the expression of gata1a by QPCR. We quantified the expression of gata1a in embryos injected with an hmgcs1 morpholino because genotyping of mutant larvae prior to RNA isolation could not be consistently achieved without rapid decay in total RNA quality. Microinjection of hmgcs1 morpholinos accurately phenocopied 1 the RBC deficits observed with the Vu57 allele ( Supplementary Figure 2 ) and QPCR confirmed a near 70% reduction in gata1a expression in morphants ( Figure 3A -D&3I, p<0.05).
We next measured gata1a expression in wildtype embryos treated with 2uM atorvastatin (ATOR), a drug that inhibits the rate-limiting step of the cholesterol synthesis pathway 47 , and should mimic the effects of mutations in hmgcs1. gata1a expression was decreased in ATOR treated embryos relative to vehicle control ( Figure 3E -F, arrowheads, p=0.0001) and QPCR confirmed that ATOR treatment caused a significant reduction in gata1a expression ( Figure 3J , p<0.05). We next confirmed these results by treating Tg(gata1a:dsRed) larvae with 2uM ATOR or vehicle control. Treatment with ATOR caused an approximate 50% decrease in the number of dsRed positive cells ( Figure 3G , H&K p=7.25273E-07). Collectively, these data suggest that the Vu57 allele decreases the number of Gata1a positive cells produced during primitive erythropoiesis.
Cholesterol and Isoprenoids regulate RBC development.
Mutation of hmgcs1 disrupts the first enzyme of the CSP 34 effectively interfering with the production of both cholesterol and isoprenoids. Recent evidence suggests that each of these two lipids can regulate the same biological process, however by independent molecular and cellular mechanisms 34, 35, 37 . We hypothesized that the defects observed in mutant larvae are cholesterol dependent. We treated wildtype embryos with either vehicle control (DMSO), 1.5uM
Ro 48 8071, to inhibit cholesterol, but not isoprenoids, 8uM lonafarnib, to inhibit farnesylated isoprenoids, but not cholesterol or 2uM ATOR, a control to mimic the Vu57 allele. According to o-dianisidine, vehicle treated embryos (DMSO) exhibited the appropriate number and spatial organization of RBCs in the ventral head vessels at 4 dpf ( Figure 4A ). Notably, treatment with ATOR induced a cerebral hemorrhage that was not consistent with the Vu57 allele ( Figure 4B ).
Embryos treated with 1.5uM Ro 48 8071 or 8uM lonafarnib had visibly fewer RBCs ( Figure 4A -D p=0.0001), suggesting that cholesterol synthesis is required for RBC development. Cerebral hemorrhages were not observed upon treatment with Ro 48 8071 or lonafarnib. We further quantified the total hemoglobin content from larvae treated with each drug or vehicle control. As shown in Figure 4E , treatment with each drug resulted in a statistically significant decrease in total hemoglobin content. Drug treatment resulted in a more marked decrease in hemoglobin concentration relative to larvae harboring the Vu57 allele (Figure 1 ). This can likely be attributed to the fact that we performed a comparison between homozygous carriers of the Vu57 allele with a pool of heterozygous and wildtype homozygous individuals suggesting that heterozygous individuals demonstrate some degree of deficits in RBC development. Taken together, these data raise the possibility that the synthesis of cholesterol and isoprenoids is essential for RBC development/differentiation. gata1a expression is isoprenoid dependent.
The Vu57 allele results in decreased gata1a expression and increased hbbe1.1 expression. Therefore, we measured the expression of each gene in wildtype embryos treated with vehicle control (DMSO), 1.5uM Ro 48 8071, or 8uM lonafarnib using ISH at 26 hpf. hbbe1.1
expression was localized to the caudal most region of the ICM and over the yolk sac in vehicle control embryos ( Figure 5A ). Inhibition of cholesterol or isoprenoids caused a statistically significant increase in hbbe1.1 mRNA ( Figure 5G , p<0.05) that was visible over the yolk sac ( Figure 5A-C, p=0.0001) . The level and spatial expression of hbbe1.1 is consistent with those observed in embryos carrying the Vu57 allele ( Figure 2) . Interestingly, the expression of gata1a was not affected by treatment with 1.5uM Ro 48 8071, but was significantly decreased when isoprenoid synthesis was inhibited ( Figure 5D -F; Figure 5H , p<0.05). The decrease in gata1a expression was consistent with a decrease in the number of Gata1 + cells as demonstrated by the Tg(gata1a:dsRed) ( Figure 5I, p=2 .7125E-07) Collectively, these data suggest that isoprenoids regulate RBC differentiation in a gata1a dependent manner.
Discussion
Here we show that cholesterol and isoprenoids regulate erythropoiesis using a zebrafish harboring mutations in the hmgcs1 gene (Vu57 allele). Mutations in human HMGCS1 have not been associated with disease, but there are 8 congenital anomalies that occur as a consequence of mutations within other enzymes of the CSP [5] [6] [7] [8] [9] [10] [11] 13, 48 . These congenital anomalies are characterized by diverse phenotypes 7, 21, [48] [49] [50] and mutations in the zebrafish hmgcs1 gene mimics these disorders resulting in a multiple congenital anomaly syndrome.
Therefore, zebrafish with mutations in hmgcs1 have the potential to reveal novel cellular and molecular mechanisms underlying individual phenotypes across multiple genetic disorders.
Cholesterol represents approximately ½ the weight of a RBC membrane and governs membrane fluidity, transport, reversible deformations and survival in response to oxidative stress 51, 52 . In addition cholesterol is a precursor for multiple molecules including bile acid, vitamin D, and steroid hormones and deficiencies in cholesterol synthesis interfere with proper RBC development 23, 24 . Based upon these data, we hypothesized that mutation of hmgcs1 would disrupt erythropoiesis in vivo. We found that homozygous mutations in hmgcs1 cause a decrease in the number of hemoglobinized RBCs and total hemoglobin content, consistent with previous work 24 demonstrating that defects in RBC number can be rescued by the exogenous injection of water soluble cholesterol. Our study using the Vu57 allele establishes that the products of the CSP are essential for proper RBC homeostasis, however, the mechanism by which the CSP exerts these effects is yet to be elucidated. Given the role of cholesterol in the RBC membrane, it is plausible that cholesterol regulates cell survival. However, the function of the CSP might not be limited to cell death or stress mechanisms because previously published work has indicated a regulatory function for cholesterol and its derivatives at the level of cellular differentiation [53] [54] [55] [56] [57] [58] [59] [60] . Future work that analyzes both primitive and definitive hematopoiesis at unique stages of differentiation in different model systems is likely to identify the exact cellular mechanisms underlying the phenotypic alteration we describe. The closely related zebrafish mutant of hmgcrb will be of great utility, as we hypothesize that mutation in hmgcrb 36 will produce overlapping phenotypes with the Vu57 allele.
The GATA family of transcription factors are essential mediators of erythropoiesis.
Specifically, the expression of GATA1 signals the commitment of a common myeloid progenitor towards an erythroid fate. Numerous studies have confirmed that the expression of GATA1 is at the center of at least two axis governing cell fate decisions. The expression of GATA1 represses the expression of GATA2, a second member of the family whose expression promotes a progenitor cell fate 15, 61 . GATA1 expression also antagonizes the expression of SPI-1, which promotes myeloid differentiation 62, 63 . Here we demonstrate for the first time that the expression of gata1a, the zebrafish ortholog of GATA1, is linked to the CSP. Moreover, we establish that expression of gata1a is isoprenoid dependent. where cerebral hemorrhages are observed. This phenotype is not consistently observed with the Vu57 allele or larvae treated with lornafarnib or Ro 48 8071, but has been reported in hmgcrb mutants 36 . Despite the presence of cerebral hemorrhages in atorvastatin treated embryos, we still observe a statistically significant decrease in total hemoglobin content in these larvae. Thus, suggesting that inhibition of the CSP reduces total hemoglobin content, which is consistent with an accumulation of globin and alas2 RNA. These results are further supported by in vitro studies of GATA1 deletion where GATA1 negative cells undergo developmental arrest, but maintain expression of GATA target genes, including globin 64 .
Our data establishes that isoprenoid synthesis is essential for appropriate gata1a expression. These effects are likely to be indirect because isoprenoids are a large class of molecules with diverse functions. Retinoids are an isoprenoids derivative 65 and retinoic acid is one potential regulator of blood cell differentiation because previous studies have established that retinoic acid signaling increases the number of HSCs 30, 31, 33 and mediates the formation of HSCs from the mesoderm 66 . However, these mechanisms are likely to be complex and stage specific because retinoic acid has been shown to decrease the expression of gata1 in zebrafish 67 . Thus, retinoic acid is only one potential mediator of erythropoiesis.
Here we demonstrate that cholesterol and isoprenoids, two products of the CSP Our study focuses on the regulation of GATA1 expression, primarily in the context of isoprenoids. Given the role of isoprenoids in development and signaling, it is likely that they are a positive upstream regulator of gata1a. Therefore, future work in this area may identify novel therapeutic targets for various disorders. For example, mutation of mevalonate kinase causes mevalonate kinase deficiency (MVD) 70, 71 . Mevalonate kinase is central to the cholesterol synthesis pathway and converts mevalonate to 5'phosphomevalonate. 5'phosphomevalonate is the substrate for future enzymatic reactions that culminate with the creation of cholesterol and isoprenoids and therefore mutations in this kinase disrupt the synthesis of both cholesterol and isoprenoids. Patients with MVD exhibit with hematological deficiencies and extramedullary hematopoiesis 72 , but the mechanisms underlying these phenotypes are not fully characterized.
However, mutations in mevalonate kinase are likely to be recapitulated in zebrafish with mutations in hmgcs1 or hmgcrb. Therefore, our system has the potential to understand the mechanisms governing GATA1 expression, a central transcriptional regulator of primitive hematopoiesis.
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